February 19, 2026
Investors in the former Mylan NV have reached a $60 million settlement with the company over claims the drugmaker manipulated quality control measures at a West Virginia facility and lied to shareholders, the investors told a federal court this week.
July 08, 2025
A Pennsylvania federal judge on Tuesday denied a win for former pharmaceutical company Mylan NV in a proposed shareholder class action accusing the company of manipulating quality control tests at a West Virginia plant, saying the plaintiff has met the burden of showing a link between misrepresentations and financial losses.
May 19, 2023
A Pennsylvania federal judge cut down a proposed stockholder class action against pharmaceutical company Mylan NV that alleges it artificially increased its stock price by manipulating quality control tests at a West Virginia plant, ruling that several of the alleged misrepresentations included in the complaint are not actionable.
March 14, 2023
Former executives at Mylan NV didn't have personal knowledge of quality control or regulatory issues at a West Virginia pharmaceutical plant, nor did they have a duty to tell investors all the details when the U.S. Food and Drug Administration stepped in, counsel for the company told a Pennsylvania federal judge Tuesday.
January 20, 2021
Pharmaceutical company Mylan NV told a Pennsylvania federal judge Tuesday he should toss a proposed class action alleging securities fraud because the company made "unvarnished disclosures" about its quality assurance and compliance with the U.S. Food and Drug Administration's regulations.
September 15, 2020
The law firms of Bernstein Litowitz and Kessler Topaz will lead a proposed investor class-action lawsuit brought by Mississippi retirees against Mylan NV over allegedly falsified quality controls at a West Virginia plant, a Pennsylvania federal judge said.
June 29, 2020
A public employee pension fund launched a class action in Pennsylvania federal court on Friday accusing Mylan NV of artificially pumping up its stock price by manipulating quality control tests at a West Virginia plant before eventually being exposed by a pair of whistleblowers and subsequent federal investigations.